Skip to main content

Table 1 Patient Demographics

From: I Design of the Primary Prevention Parameters Evaluation (PREPARE) trial of implantablecardioverter defibrillators to reduce patient morbidity [NCT00279279]

 

PREPARE Patients

(N = 700)

MIRACLE ICD Patients

(N = 415)

EMPIRIC Patients

(N = 276)

Combined Control (MIRACLE ICD and EMPIRIC) Patients

(N = 691)

Gender (N, %)

    

   Male

555 (79.3%)

310 (74.7%)

222 (80.4%)

532 (77%)

   Female

145 (20.7%)

105 (25.3%)

54 (19.6%)

159 (23%)

Age (years)

    

   Mean ± Standard Deviation

67.4 ± 12.2

65.4 ± 11.5

65.6 ± 12

65.5 ± 11.7

   Median

68.7

67.9

67.3

67.7

   Minimum – Maximum

19.2 – 92.2

31 – 89

23.3 – 91.4

23.3 – 91.4

   n (%)

700 (100%)

415 (100%)

276 (100%)

691 (100%)

Baseline Left Ventricular Ejection Fraction (%)

    

   Mean ± Standard Deviation

27.7 ± 10.5

21 ± 6.8

30.3 ± 11

24.7 ± 9.8

   Median

25

20

30

25

   Minimum – Maximum

5 – 80

6 – 35

5 – 70

5 – 70

   n (%)

691 (98.7%)

413 (99.5%)

273 (98.9%)

686 (99.3%)

Baseline New York Heart Association Classification (N, %)

    

   Class I

117 (16.7%)

0 (0%)

36 (13%)

36 (5.2%)

   Class II

297 (42.4%)

137 (33%)

102 (37%)

239 (34.6%)

   Class III

268 (38.3%)

237 (57.1%)

36 (13%)

273 (39.5%)

   Class IV

18 (2.6%)

41 (9.9%)

3 (1.1%)

44 (6.4%)

   Not Collected*

0 (0%)

0 (0%)

99 (35.9%)

99 (14.3%)

Ischemic Cardiomyopathy

488 (69.7%)

238 (57.5%)

155 (56.2%)

393 (57.0%)

Myocardial Infarction (N, %)

421 (60.1%)

193 (46.6%)

192 (69.6%)

385 (55.8%)

  1. N/A = not collected
  2. *NYHA Class was only collected in the EMPIRIC Trial for patients with documented heart failure